StreetAlpha.app
Home › Stocks › GNLX

GENELUX Corp (GNLX)

Healthcare
$2.17
▼ −4.82%
LAST CLOSE · NOV 20

Genelux develops cancer immunotherapies based on a modified vaccinia virus that infects and destroys tumor cells. It last closed at $2.17 on Nov 20, down 4.82% on the day. Over the last 12 months GNLX insiders bought $0 of stock on the open market and sold $349K, according to SEC Form 4 filings.

AI Auto Pilots
Is GNLX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GNLX.

Key Stats

Fiscal 2025
Results
Revenue
$8K
+0.0% vs a year ago
Net income
−$32.1M
−401812.5% margin
EPS (diluted)
−$0.86
Free cash flow
−$26.4M
−329575.0% margin
Valuation
Market cap
$104.3M
48.1M shares
P/E
–
No P/E while losing money
Price to sales
13037.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.4M
At Sep 30
Shareholder equity
$9.2M
Shares outstanding
48.1M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $11.1M$11.1MFY2022FY2023: $170K$170KFY2023FY2024: $8K$8KFY2024FY2025: $8K$8KFY2025

From GNLX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 16).

Last report
Mar 25
2025 · next date not set yet
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How GNLX moved after its last 2 reports
Average move the session after a report ±12.6%
Mar 25, 2025Time not announced−12.6%
Feb 2, 2024After the close−12.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GNLXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GNLX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GNLX

Technical Analysis

GNLX · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 22% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the Pivot S1 at $2.06, and the nearest resistance the Pivot at $2.23.

Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 9.0%/day
Key levels
$5.8952 week high+171.4%
$2.64200 day average+21.7%
$2.53100 day average+16.6%
$2.35Pivot R1+8.3%
$2.2850 day average+5.1%
$2.27Swing high (Oct 29)+4.6%
$2.23Pivot+2.8%
$2.17Last close
$2.06Pivot S1−5.1%
$2.0120 day average−7.4%
$1.86Swing low (Oct 27)−14.3%
$1.7752 week low−18.4%
Indicators
RSI (14)52.25Middle of its rangeNeutral
MACD-0.04Above its signal lineBullish
Stochastic81.9Near the top of its rangeOverbought
ADX (14)17.0No clear trend
Williams %R-37.5Oversold below −80, overbought above −20Neutral
CCI (20)151.1Oversold below −100, overbought above 100Overbought
Rate of change+10.7%Change over 10 sessionsBullish
ATR (14)$0.19Typical daily range, 9.0% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for GNLX

What happened before

See how GNLX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GNLX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GNLX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GNLXHow many large options trades hit GNLX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

GNLX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲30 buying vs 22 selling
  • ▲Held by funds +0.9 pts
  • ▲Funds holding +6
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7872+8.3%
In funds' top 10110.0%
Held by funds21.3%20.4%+0.9 pts
New / increased14 / 1610 / 18+7.1%
Reduced / sold out14 / 815 / 10−12.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GNLX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GNLX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$349K23 sales · 6 insiders
31% of the selling was under pre-arranged trading plans.
2025-12 sold $59K2026-03 sold $43K2026-05 sold $13K2026-06 sold $30K2026-07 sold $35K2026-08 sold $159K2026-11 sold $9KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 3Yong YuChief Scientific OfficerSale668$2.01$1K
Nov 3Thomas ZindrickPresident and CEOSale3,089$2.05$6K
Nov 3Joseph CappelloChief Technical OfficerSale668$2.04$1K
Aug 31Yong YuChief Scientific OfficerSale9,683$2.75$27K
Aug 31Thomas ZindrickPresident and CEOSale34,463$2.67$92K
Aug 31Joseph CappelloChief Technical OfficerSale10,257$2.74$28K
Every insider buy and sale for GNLX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GNLX insider trades →

From SEC Form 4 filings by GNLX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GNLX is in one of them and how their past GNLX trades turned out.

GNLX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GNLX in an article yet. Here's the latest on the wider market.

About GENELUX

Genelux is a biopharmaceutical company based in Westlake Village, California, that develops cancer treatments built on a modified vaccinia virus. Its lead candidate, Olvi-Vec, is designed to infect and destroy tumor cells while prompting the immune system to attack cancer throughout the body. The company is testing it in ovarian cancer, lung cancer and small cell lung cancer, aiming at patients whose tumors have responded poorly to standard treatments such as chemotherapy. It also operates a manufacturing facility in San Diego and has licensed rights to Olvi-Vec in China to a partner.

Headquarters
Westlake Village, CA